Accolade's (ACCD) "Hold" Rating Reiterated at Needham & Company LLC

Accolade (NASDAQ:ACCD - Get Free Report)'s stock had its "hold" rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

Several other equities research analysts have also recently weighed in on ACCD. Canaccord Genuity Group dropped their target price on Accolade from $13.00 to $7.00 and set a "buy" rating for the company in a report on Wednesday, October 9th. Wells Fargo & Company decreased their target price on shares of Accolade from $7.00 to $6.00 and set an "equal weight" rating on the stock in a research note on Friday, October 11th. Morgan Stanley lowered their price target on shares of Accolade from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Stephens cut their price target on shares of Accolade from $10.00 to $8.00 and set an "overweight" rating on the stock in a report on Wednesday, October 9th. Finally, Leerink Partners reaffirmed a "market perform" rating on shares of Accolade in a research note on Wednesday. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Accolade has an average rating of "Moderate Buy" and a consensus target price of $8.96.

Accolade Price Performance

NASDAQ:ACCD traded up $3.51 during mid-day trading on Wednesday, reaching $6.86. The stock had a trading volume of 24,720,332 shares, compared to its average volume of 5,725,401. Accolade has a one year low of $3.08 and a one year high of $15.36. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.72 and a current ratio of 2.72. The firm has a 50 day moving average price of $3.52 and a two-hundred day moving average price of $3.79. The stock has a market capitalization of $552.48 million, a P/E ratio of -6.66 and a beta of 2.08.

Accolade (NASDAQ:ACCD - Get Free Report) last announced its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.14. The company had revenue of $106.40 million during the quarter, compared to analysts' expectations of $104.87 million. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. The firm's revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.43) EPS. As a group, analysts expect that Accolade will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Accolade

In related news, CEO Rajeev Singh sold 13,357 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the sale, the chief executive officer now owns 814,316 shares in the company, valued at $2,931,537.60. This represents a 1.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 42,006 shares of company stock valued at $149,228. 8.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Accolade

A number of institutional investors have recently modified their holdings of the stock. Millennium Management LLC raised its position in Accolade by 244.7% in the 2nd quarter. Millennium Management LLC now owns 2,623,201 shares of the company's stock worth $9,391,000 after buying an additional 1,862,178 shares during the last quarter. Whetstone Capital Advisors LLC bought a new position in Accolade during the third quarter valued at approximately $3,842,000. Clearline Capital LP purchased a new stake in Accolade in the second quarter worth approximately $2,974,000. Point72 Asset Management L.P. bought a new stake in Accolade in the 3rd quarter worth approximately $2,378,000. Finally, Johnson Financial Group LLC purchased a new stake in Accolade during the 3rd quarter valued at $1,642,000. 84.99% of the stock is owned by hedge funds and other institutional investors.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.